multicentre phase III randomised trial comparing Doxorubicin and Cycl

• Research type

  Research Study

• Full title

  A multicentre phase III randomised trial comparing Doxorubicin and Cyclosphamide Followed by Docetaxel (AC-T) with Doxorubicin and Cyclosphamide followed by Docetaxel and Trastuzmab (AC-TH)and with Docetaxel, platinum Salt and Trastuzumab (TCH)In the threatment of Node Positive and High Risk Node Negative Adjuvant Patients with Operable Breast Cancer Containing The HER2NEU Alteration.

• Contact name

  K E Sherwin

• Sponsor organisation

  Sanofi-aventis

• ISRCTN Number

  ISRCTN

• Research summary

  Research Summary not yet available

• REC name

  London - Central Research Ethics Committee

• REC reference

  01/2/17

• Date of REC Opinion

  5 Jan 2011

• REC opinion

  Favourable Opinion